Sarcoma
PRINCIPAL INVESTIGATORS
- Francisco Javier Garcia Del Muro Solans
CLINICAL RESEARCHERS
- Francesc Xavier Sanjuan Garriga
POSTDOCTORAL RESEARCHERS
- Mariona Chicón Bosch
PREDOCTORAL RESEARCHERS
- Sara Sanchez Serra
SCIENTIFIC SUPPORT
- Rosario Lopez Alemany
- Manuel Gris Lorente
- Marta Rosas Lapeña
Cancer
Oncobell
Scientific production
12
PAPERS
Average IF: 18,52
4
LED PAPER
Average IF: 4,33
4 PUBLICATIONS IN FIRST DECILE
9 PUBLICATIONS IN FIRST QUARTILE
5 PUBLICATIONS IN OPEN ACCESS
Selected publications
- Choueiri,TK;Powles,T;Peltola,K;de Velasco,G;Burotto,M;Suarez,C;Ghatalia,P et al, Belzutifan versus Everolimus for Advanced Renal-Cell Carcinoma, N Engl J Med, 2024;391(8):710-721, doi:10.1056/NEJMoa2313906
- Bamias,A;Davis,I;Galsky,M;Arranz,JA;Kikuchi,E;Grande,E;Muro,XGD et al, Atezolizumab monotherapy versus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis from a randomised, controlled, phase 3 study, Lancet Oncol, 2024;25(1):46-61, doi:10.1016/S1470-2045(23)00539-9
- Grande,E;Arranz,JA;De Santis,M;Bamias,A;Kikuchi,E;del Muro,XG;Park,SH et al, Atezolizumab plus chemotherapy versus placebo plus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis results from a randomised, controlled, phase 3 study, Lancet Oncol, 2024;25(1):29-45, doi:10.1016/S1470-2045(23)00540-5
- GARCIA DEL MURO,X;Paez Lopez Bravo,D;Cuellar Rivas,MA;Maroto,P;Giannatempo,P;Castellano,D;Climent,MA et al, Retifanlimab in Advanced Penile Squamous Cell Carcinoma: The Phase 2 ORPHEUS Study., Eur Urol Oncol, 2024;doi:10.1016/j.euo.2024.04.021
- Bührer,E;D’Haese,D;Daugaard,G;de Wit,R;Albany,C;Tryakin,A;Fizazi,K et al, Impact of teratoma on survival probabilities of patients with metastatic non-seminomatous germ cell cancer: Results from the IGCCCG Update Consortium, Eur J Cancer, 2024;202114042-114042, doi:10.1016/j.ejca.2024.114042
Research highlights
PROJECTS
5 Ongoing competitive projects
5 Started clinical trials
31 Ongoing clinical trials
PUBLISHED WORKS
1 Clinical guideline
1 Thesis
INNOVATION
1 Patent
1 License
1 Spin off
NETWORKS
AGAUR SGR GRC
Selected projects
- ICI23/00065. Terapia de tumores de células germinales basada en linfocitos infiltrantes de tumores autólogos (ARES). Instituto de Salud Carlos III (ISCIII). Budget: 1.205,077,03€. 2024-2027. PI: GARCIA DEL MURO SOLANS, FRANCISCO JAVIER.
- 2018-002520-16. ENSAYO DE FASE 3, ALEATORIZADO Y CONTROLADO CON PLACEBO PARA EVALUAR LA SEGURIDAD Y LA EFICACIA DE PEMBROLIZUMAB (MK-3475) Y LENVATINIB (E7080/MK-7902) EN COMPARACIÓN CON PEMBROLIZUMAB EN MONOTERAPIA COMO INTERVENCIÓN DE PRIMERA LÍNEA EN PARTICIPANTES CON MELANOMA AVANZADO (LEAP-003). MERCK SHARP & DOHME ESPAÑA S.A. Budget: 376.776€. 2019-2025. PI: MARTIN LIBERAL, JUAN JESUS.
- 2022-501105-12-00. AN OPEN-LABEL, RANDOMIZED, CONTROLLED PHASE 3 STUDY OF DISITAMAB VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB VERSUS CHEMOTHERAPY IN SUBJECTS WITH PREVIOUSLY UNTREATED LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA THAT EXPRESSES HER2 (IHC 1+ AND GREATER. Seagen Inc. Budget: 349.209,9€. 2024- . PI: GARCIA DEL MURO SOLANS, FRANCISCO JAVIER.
- 2023-504231-41-00. A RADOMIZED OPEN-LABEL PHASE 2/3 STUDY OF BT8009 AS MONOTHERAPY OR IN COMBINATION IN PARTICIPANTS WITH LOCALLY ADVANCED OR METASTASIC UROTHERUAK CABCER (DURAVELO-2). BYCYCLETX LIMITED. Budget: 210.840€. 2024- . PI: GARCIA DEL MURO SOLANS, FRANCISCO JAVIER.
- CPP2021-008515. TRASLACIÓN A LA CLÍNICA DE UNA NUEVA TERAPIA DIRIGIDA PARA EL TRATAMIENTO DEL SARCOMA DE EWING. Ministerio de Ciencia e Innovación. Budget: 199.904,74€. 2022-2025. PI: MARTINEZ TIRADO, OSCAR.